UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A review of cost studies of intensive care units: Problems with the cost concept

Critical care medicine, 1995-05, Vol.23 (5), p.964-972

Marlene Gyldmark, Cand.Polit

1995

Volltextzugriff (PDF)

EE420 Use of a Cost-Tool to Support Decisions on Resource Allocation in the US Type 2 Diabetes Population Using Glucose Monitoring Devices

Value in health, 2022-07, Vol.25 (7), p.S417

2022

Volltextzugriff (PDF)

Cost-Effectiveness of Erlotinib versus Docetaxel for Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer in the United Kingdom

Journal of international medical research, 2010-01, Vol.38 (1), p.9-21

2010

Volltextzugriff (PDF)

TRASTUZUMAB TREATMENT OF EARLY STAGE BREAST CANCER IS COST-EFFECTIVE FROM THE PERSPECTIVE OF THE BELGIAN HEALTH CARE AUTHORITIES

Acta clinica belgica (English ed. Online), 2009-04, Vol.64 (2), p.100-112

2009

Volltextzugriff (PDF)

PDB32 Integration of Patient-Reported Outcome Measures in the Evaluation of Digital Health Solutions: Research in Diabetes

Value in health, 2021-06, Vol.24, p.S83-S83

2021

Volltextzugriff (PDF)

PHP306 - Global Evaluation of European Submission Template to Inform HTA and Payer Submissions

Value in health, 2016-11, Vol.19 (7), p.A493-A494

2016

Volltextzugriff (PDF)

The cost of measles in industrialised countries

Vaccine, 2003-10, Vol.21 (27), p.4167-4177

2003

Volltextzugriff (PDF)

6617 POSTER Does the use of erlotinib for the treatment of relapsed stage IIIB/IV NSCLC patients improve quality-adjusted survival compared with docetaxel?

European journal of cancer supplements, 2007, Vol.5 (4), p.393-393

2007

Volltextzugriff (PDF)

IN2 IS PROVISION OF ANTI-VIRAL INFLUENZA TREATMENT A SOUND INVESTMENT FOR PRIVATE AND PUBLIC EMPLOYERS IN THE UK?

Value in health, 2004-11, Vol.7 (6), p.638-639

2004

Volltextzugriff (PDF)

PCN69 COST-EFFECTIVENESS OF FIRST-LINE COMBINATION TREATMENT WITH BEVACIZUMAB PLUS FOLFIRI VERSUS FOLFIRI IN PATIENTS WITH METASTATIC COLORECTAL CANCER: A UK PERSPECTIVE

Value in health, 2009, Vol.12 (3), p.A49-A49

2009

Volltextzugriff (PDF)

PCN70 MODELLING THE COST EFFECTIVENESS OF FIRST-LINE COMBINATION TREATMENT WITH BEVACIZUMAB PLUS IRINOTECAN AND INFUSIONAL FLUOROPYRIMIDINES VERSUS IRINOTECAN AND INFUSIONAL FLUOROPYRIMIDINES IN METASTATIC COLORECTAL CANCER PATIENTS IN SWEDEN

Value in health, 2009, Vol.12 (3), p.A49-A49

2009

Volltextzugriff (PDF)

PIN37 INTRODUCTION OF A NEW HEALTH TECHNOLOGY, POTENTIAL BEHAVIOURAL AND ORGANISATIONAL CHANGES AND POLICY IMPACT—ASSESSMENT OF NEW INFLUENZA TREATMENTS

Value in health, 2003-11, Vol.6 (6), p.759-759

2003

Volltextzugriff (PDF)

PIN11 COST-EFFECTIVENESS OF OSELTAMIVIR FOR THE TREATMENT OF INFLUENZA IN ADULTS AND CHILDREN IN FINLAND

Value in health, 2006-11, Vol.9 (6), p.A302-A302

2006

Volltextzugriff (PDF)

CN5 EXPLORATORY ECONOMIC EVALUATION OF ADJUVANT TREATMENT OF NON-SMALL-CELL LUNG CANCER (NSCLC) WITH BEVACIZUMAB IN ADDITION TO A CISPLATIN-BASED TREATMENT REGIMEN IN THE UNITED KINGDOM

Value in health, 2008, Vol.11 (6), p.A357-A357

2008

Volltextzugriff (PDF)

Demand for health care in Denmark: results of a national sample survey using contingent valuation

Social science & medicine (1982), 2001-10, Vol.53 (8), p.1023-1036

2001

Volltextzugriff (PDF)

CN3 PHARMACOECONOMIC (PE) ANALYSIS OF THE TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC) IN THE NETHERLANDS DEMONSTRATES THAT ERLOTINIB DOMINATES DOCETAXEL AND IS COST-EFFECTIVE OVER BEST SUPPORTIVE CARE (BSC) WITHOUT NEED FOR PATIENT STRATIFICATION

Value in health, 2006-11, Vol.9 (6), p.A203-A203

2006

Volltextzugriff (PDF)

PMC33 GUIDELINES FOR ENSURING DEGREES OF VALIDITY IN HEALTH ECONOMIC MODELS

Value in health, 2007, Vol.10 (6), p.A460-A461

2007

Volltextzugriff (PDF)

PCN12 COST EFFECTIVENESS OF ERLOTINIB IN THE TREATMENT OF ADVANCED NON SMALL CELL LUNG CANCER (NSCLC) IN POLAND

Value in health, 2006-11, Vol.9 (6), p.A279-A279

2006

Volltextzugriff (PDF)

PCN11 PHARMACOECONOMIC ANALYSES OF ERLOTINIB COMPARED WITH BEST SUPPORTIVE CARE (BSC) FOR THE TREATMENT OF RELAPSED NON-SMALL CELL LUNG CANCER (NSCLC) FROM THE CANADIAN PUBLIC HEALTH CARE PERSPECTIVE

Value in health, 2006-11, Vol.9 (6), p.A279-A279

2006

Volltextzugriff (PDF)

Post-exposure influenza prophylaxis with oseltamivir cost effectiveness and : Cost utility in families in the UK

PharmacoEconomics, 2006-01, Vol.24 (4), p.373-386

2006

Volltextzugriff (PDF)

PCN7 COST-EFFECTIVENESS ANALYSIS OF ADJUVANT THERAPY WITH TRASTUZUMAB FOR HER2-POSITIVE EARLY BREAST CANCER IN POLISH SETTING

Value in health, 2007, Vol.10 (3), p.A125-A125

2007

Volltextzugriff (PDF)

Effect of influenza treatment with oseltamivir on health outcome and costs in otherwise healthy children

Clinical drug investigation, 2004-01, Vol.24 (7), p.395-407

2004

Volltextzugriff (PDF)

CN4 COST-EFFECTIVENESS OF ERLOTINIB COMPARED WITH DOCETAXEL FOR THE TREATMENT OF RELAPSED NONSMALL CELL LUNG CANCER (NSCLC) IN THE UK

Value in health, 2006-11, Vol.9 (6), p.A203-A204

2006

Volltextzugriff (PDF)

PCN40 COST EFFECTIVENESS OF RITUXIMAB PLUS CVP IN PREVIOUSLY UNTREATED INDOLENT NON-HODGKIN'S LYMPHOMA

Value in health, 2006-11, Vol.9 (6), p.A288-A288

2006

Volltextzugriff (PDF)

PCN18 A SENSITIVITY ANALYSIS OF THE COST PER QUALITY ADJUSTED LIFE YEAR (QALY) OF TRASTUZUMAB IN THE TREATMENT OF EARLY BREAST CANCER (EBC)

Value in health, 2006-11, Vol.9 (6), p.A281-A281

2006

Volltextzugriff (PDF)

1 – 25 von 39

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(37)
Mit Volltextzugriff
(36)

Publikationsform

Artikel
(39)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A review of cost studies of intensive care units: Problems with the cost concept

EE420 Use of a Cost-Tool to Support Decisions on Resource Allocation in the US Type 2 Diabetes Population Using Glucose Monitoring Devices

Cost-Effectiveness of Erlotinib versus Docetaxel for Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer in the United Kingdom

TRASTUZUMAB TREATMENT OF EARLY STAGE BREAST CANCER IS COST-EFFECTIVE FROM THE PERSPECTIVE OF THE BELGIAN HEALTH CARE AUTHORITIES

PDB32 Integration of Patient-Reported Outcome Measures in the Evaluation of Digital Health Solutions: Research in Diabetes

PHP306 - Global Evaluation of European Submission Template to Inform HTA and Payer Submissions

The cost of measles in industrialised countries

6617 POSTER Does the use of erlotinib for the treatment of relapsed stage IIIB/IV NSCLC patients improve quality-adjusted survival compared with docetaxel?

IN2 IS PROVISION OF ANTI-VIRAL INFLUENZA TREATMENT A SOUND INVESTMENT FOR PRIVATE AND PUBLIC EMPLOYERS IN THE UK?

PCN69 COST-EFFECTIVENESS OF FIRST-LINE COMBINATION TREATMENT WITH BEVACIZUMAB PLUS FOLFIRI VERSUS FOLFIRI IN PATIENTS WITH METASTATIC COLORECTAL CANCER: A UK PERSPECTIVE

PCN70 MODELLING THE COST EFFECTIVENESS OF FIRST-LINE COMBINATION TREATMENT WITH BEVACIZUMAB PLUS IRINOTECAN AND INFUSIONAL FLUOROPYRIMIDINES VERSUS IRINOTECAN AND INFUSIONAL FLUOROPYRIMIDINES IN METASTATIC COLORECTAL CANCER PATIENTS IN SWEDEN

PIN37 INTRODUCTION OF A NEW HEALTH TECHNOLOGY, POTENTIAL BEHAVIOURAL AND ORGANISATIONAL CHANGES AND POLICY IMPACT—ASSESSMENT OF NEW INFLUENZA TREATMENTS

PIN11 COST-EFFECTIVENESS OF OSELTAMIVIR FOR THE TREATMENT OF INFLUENZA IN ADULTS AND CHILDREN IN FINLAND

CN5 EXPLORATORY ECONOMIC EVALUATION OF ADJUVANT TREATMENT OF NON-SMALL-CELL LUNG CANCER (NSCLC) WITH BEVACIZUMAB IN ADDITION TO A CISPLATIN-BASED TREATMENT REGIMEN IN THE UNITED KINGDOM

Demand for health care in Denmark: results of a national sample survey using contingent valuation

CN3 PHARMACOECONOMIC (PE) ANALYSIS OF THE TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC) IN THE NETHERLANDS DEMONSTRATES THAT ERLOTINIB DOMINATES DOCETAXEL AND IS COST-EFFECTIVE OVER BEST SUPPORTIVE CARE (BSC) WITHOUT NEED FOR PATIENT STRATIFICATION

PMC33 GUIDELINES FOR ENSURING DEGREES OF VALIDITY IN HEALTH ECONOMIC MODELS

PCN12 COST EFFECTIVENESS OF ERLOTINIB IN THE TREATMENT OF ADVANCED NON SMALL CELL LUNG CANCER (NSCLC) IN POLAND

PCN11 PHARMACOECONOMIC ANALYSES OF ERLOTINIB COMPARED WITH BEST SUPPORTIVE CARE (BSC) FOR THE TREATMENT OF RELAPSED NON-SMALL CELL LUNG CANCER (NSCLC) FROM THE CANADIAN PUBLIC HEALTH CARE PERSPECTIVE

Post-exposure influenza prophylaxis with oseltamivir cost effectiveness and : Cost utility in families in the UK

PCN7 COST-EFFECTIVENESS ANALYSIS OF ADJUVANT THERAPY WITH TRASTUZUMAB FOR HER2-POSITIVE EARLY BREAST CANCER IN POLISH SETTING

Effect of influenza treatment with oseltamivir on health outcome and costs in otherwise healthy children

CN4 COST-EFFECTIVENESS OF ERLOTINIB COMPARED WITH DOCETAXEL FOR THE TREATMENT OF RELAPSED NONSMALL CELL LUNG CANCER (NSCLC) IN THE UK

PCN40 COST EFFECTIVENESS OF RITUXIMAB PLUS CVP IN PREVIOUSLY UNTREATED INDOLENT NON-HODGKIN'S LYMPHOMA

PCN18 A SENSITIVITY ANALYSIS OF THE COST PER QUALITY ADJUSTED LIFE YEAR (QALY) OF TRASTUZUMAB IN THE TREATMENT OF EARLY BREAST CANCER (EBC)

Suchergebnisse filtern